[CLSTR]
< Back to situation

[REVISION HISTORY]

Xeris Biopharma financial performance and analyst updates

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-10 07:13 UTC → 2026-08-10 22:21 UTC · added removed

Xeris Biopharma reported significant growth in its Recorlev revenue, which rose 81% year-over-year to approximately $56.8 million in the second quarter of 2026. The company also received a U.S. patent notice for Keveyis, extending its intellectual property protection through 2039. Following this, the company reported quarterly revenue of $92.10 million, exceeding expectations, though its earnings per share (EPS) of ($0.18) missed consensus estimates. In response to these financial results, HC Wainwright lowered its Q3 2026 EPS forecast from $0.02 to $0.01. Other analysts have also adjusted their ratings for the stock, moving from "strong-buy" ‘strong-buy’ to "buy" ‘buy’ or from "sell" ‘sell’ to "hold." ‘hold.’

Versions

  1. 2026-08-10 22:21 UTC Xeris Biopharma financial performance and analyst updates
  2. 2026-08-10 07:13 UTC Xeris Biopharma financial performance and analyst updates

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.